一种用于高级别前列腺癌的18基因尿液检测方法的开发与验证
本研究基于RNA测序开发了18基因尿液检测MPS2与MPS2+,并在前瞻性队列中进行盲法外部验证。在95%敏感性下,MPS2模型较现有生物标志物检测减少了更多不必要的活检,对GG2及以上和GG3及以上癌症的阴性预测值分别为95%至99%和99%。
要点
- MPS2与MPS2+模型在验证队列中的AUC分别为0.81和0.82,高于PSA单独检测的0.60。
- 在95%敏感性下,MPS2模型使初次活检人群的不必要活检减少35%至42%,重复活检人群减少46%至51%。
- MPS2模型对GG2及以上癌症的阴性预测值为95%至99%,对GG3及以上癌症为99%。
核心结论
- 一种新的18基因前列腺癌检测对高级别前列腺癌的诊断准确性高于现有生物标志物检测。
- 临床上使用该检测可在保持对高级别癌症高敏感性检测的同时有意义地减少不必要活检。
- 这些数据支持在PSA水平升高的患者中使用该新型前列腺癌生物标志物检测,以减少前列腺癌筛查的潜在危害并保留其长期获益。
研究设计与样本
- 对58 724个基因进行RNA测序分析,鉴定出54个前列腺癌标志物,其中17个为高级别癌症独特过表达的标志物。
- 将基因表达与临床因素建模为新的高级别前列腺癌尿液检测MPS2,并平行开发不含前列腺体积的MPS2和含前列腺体积的MPS2+最优模型。
- 锁定模型在一项前瞻性美国国家癌症研究所试验队列中进行盲法外部验证,数据收集时间为2008年1月至2020年12月,数据分析时间为2022年11月至2023年11月。
- 开发队列纳入761名男性,中位(IQR)年龄63(58-68)岁,中位(IQR)PSA水平5.6(4.6-7.2)ng/mL;验证队列纳入743名男性,中位(IQR)年龄62(57-68)岁,中位(IQR)PSA水平5.6(4.1-8.0)ng/mL。
主要发现
- 验证队列中151名(20.3%)活检发现高级别前列腺癌。
- 验证队列中,PSA单独检测的AUC为0.60,风险计算器为0.66,PHI为0.77,衍生2基因模型为0.76,衍生3基因模型为0.72,原始MPS模型为0.74,MPS2模型为0.81,MPS2+模型为0.82。
- 在95%敏感性下,MPS2模型使初次活检人群的不必要活检减少35%至42%(其他检测范围为15%至30%),使重复活检人群的不必要活检减少46%至51%(其他检测范围为9%至21%)。
- 在相关亚组中,MPS2模型对GG2及以上癌症的阴性预测值为95%至99%,对GG3及以上癌症的阴性预测值为99%。
关键数值与推荐
- 在95%敏感性下评估诊断准确性指标和检测的临床后果。
- GG3及以上癌症作为次要评估指标。
临床怎么用
- 原文结论指出,这些数据支持在PSA水平升高的患者中使用该新型前列腺癌生物标志物检测,以减少前列腺癌筛查的潜在危害并保留其长期获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Benefits of prostate cancer (PCa) screening with prostate-specific antigen (PSA) alone are largely offset by excess negative biopsies and overdetection of indolent cancers resulting from the poor specificity of PSA for high-grade PCa (ie, grade group [GG] 2 or greater). OBJECTIVE: To develop a multiplex urinary panel for high-grade PCa and validate its external performance relative to current guideline-endorsed biomarkers. DESIGN, SETTING, AND PARTICIPANTS: RNA sequencing analysis of 58 724 genes identified 54 markers of PCa, including 17 markers uniquely overexpressed by high-grade cancers. Gene expression and clinical factors were modeled in a new urinary test for high-grade PCa (MyProstateScore 2.0 [MPS2]). Optimal models were developed in parallel without prostate volume (MPS2) and with prostate volume (MPS2+). The locked models underwent blinded external validation in a prospective National Cancer Institute trial cohort. Data were collected from January 2008 to December 2020, and data were analyzed from November 2022 to November 2023. EXPOSURE: Protocolized blood and urine collection and transrectal ultrasound-guided systematic prostate biopsy. MAIN OUTCOMES AND MEASURES: Multiple biomarker tests were assessed in the validation cohort, including serum PSA alone, the Prostate Cancer Prevention Trial risk calculator, and the Prostate Health Index (PHI) as well as derived multiplex 2-gene and 3-gene models, the original 2-gene MPS test, and the 18-gene MPS2 models. Under a testing approach with 95% sensitivity for PCa of GG 2 or greater, measures of diagnostic accuracy and clinical consequences of testing were calculated. Cancers of GG 3 or greater were assessed secondarily. RESULTS: Of 761 men included in the development cohort, the median (IQR) age was 63 (58-68) years, and the median (IQR) PSA level was 5.6 (4.6-7.2) ng/mL; of 743 men included in the validation cohort, the median (IQR) age was 62 (57-68) years, and the median (IQR) PSA level was 5.6 (4.1-8.0) ng/mL. In the validation cohort, 151 (20.3%) had high-grade PCa on biopsy. Area under the receiver operating characteristic curve values were 0.60 using PSA alone, 0.66 using the risk calculator, 0.77 using PHI, 0.76 using the derived multiplex 2-gene model, 0.72 using the derived multiplex 3-gene model, and 0.74 using the original MPS model compared with 0.81 using the MPS2 model and 0.82 using the MPS2+ model. At 95% sensitivity, the MPS2 model would have reduced unnecessary biopsies performed in the initial biopsy population (range for other tests, 15% to 30%; range for MPS2, 35% to 42%) and repeat biopsy population (range for other tests, 9% to 21%; range for MPS2, 46% to 51%). Across pertinent subgroups, the MPS2 models had negative predictive values of 95% to 99% for cancers of GG 2 or greater and of 99% for cancers of GG 3 or greater. CONCLUSIONS AND RELEVANCE: In this study, a new 18-gene PCa test had higher diagnostic accuracy for high-grade PCa relative to existing biomarker tests. Clinically, use of this test would have meaningfully reduced unnecessary biopsies performed while maintaining highly sensitive detection of high-grade cancers. These data support use of this new PCa biomarker test in patients with elevated PSA levels to reduce the potential harms of PCa screening while preserving its long-term benefits.
引用
- Tosoian JJ, Zhang Y, Xiao L, et al. Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer. JAMA Oncol. 2024. PMID: 38635241. doi:10.1001/jamaoncol.2024.0455
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。